SILENCE THERAP. SP.ADR/1 - Asset Resilience Ratio

Latest as of December 2025: 56.17%

SILENCE THERAP. SP.ADR/1 (XRP2) has an Asset Resilience Ratio of 56.17% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€73.84 Million

≈ $86.32 Million USD Cash + Short-term Investments

Total Assets

€131.44 Million

≈ $153.67 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how SILENCE THERAP. SP.ADR/1's Asset Resilience Ratio has changed over time. Check XRP2 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down SILENCE THERAP. SP.ADR/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see XRP2 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€73.84 Million	56.17%
Total Liquid Assets	€73.84 Million	56.17%

Asset Resilience Insights

Very High Liquidity: SILENCE THERAP. SP.ADR/1 maintains exceptional liquid asset reserves at 56.17% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

SILENCE THERAP. SP.ADR/1 Industry Peers by Asset Resilience Ratio

Compare SILENCE THERAP. SP.ADR/1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Genfit S.A. PA:GNFT	Biotechnology	64.01%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	22.98%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Jiangsu GDK Biotechnology Co Ltd SHG:688670	Biotechnology	9.82%

Annual Asset Resilience Ratio for SILENCE THERAP. SP.ADR/1 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for SILENCE THERAP. SP.ADR/1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	56.17%	€73.84 Million ≈ $86.32 Million	€131.44 Million ≈ $153.67 Million	+43.34pp
2024-12-31	12.83%	€26.00 Million ≈ $30.40 Million	€202.63 Million ≈ $236.90 Million	--
2023-12-31	0.00%	€0.00 ≈ $0.00	€119.45 Million ≈ $139.65 Million	--
2022-12-31	15.19%	€19.76 Million ≈ $23.10 Million	€130.10 Million ≈ $152.10 Million	--
2021-12-31	0.00%	€0.00 ≈ $0.00	€129.83 Million ≈ $151.78 Million	--

pp = percentage points

About SILENCE THERAP. SP.ADR/1

F:XRP2 Germany Biotechnology

Market Cap

$386.55 Million

€330.64 Million EUR

Market Cap Rank

#15653 Global

#1520 in Germany

Share Price

€7.00

Change (1 day)

+10.24%

52-Week Range

€2.70 - €7.00

All Time High

€26.80